ProPhase Labs appoints Carolina Abenante as independent director effective June 20, 2025

ProPhase Labs, Inc.

Ms. Abenante will serve on Nominating and Corporate Governance Committee and as Chair of Compensation Committee.
Her term expires July 18, 2025, at the annual meeting; she is nominated for election to a full term.
She will be appointed to the Audit Committee effective July 19, 2025, subject to independence and financial literacy.
Ms. Abenante is founder of NYIAX and holds multiple law degrees; she receives $48,000 annual retainer and equity participation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carolina Abenante

independent director

PRPH · ProPhase Labs, Inc.

Effective: 2025-06-20
Filed: June 25, 2025, 7:59 PM ET

On June 20, 2025, the Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Carolina Abenante was appointed as independent director at ProPhase Labs, Inc..

Action: appointed
Role: independent director

Exact text from the filing

On June 20, 2025, the Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board.

View on SEC.gov

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-016501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.